Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 4, 1999, Pages 497-504

  Cone, James ^a   Wang, Sheng ^a   Tandon, Narendra ^a   Fong, Miranda ^a   Sun, Bing ^a   Sakurai, Kazushi ^a   Yoshitake, Masuhiro ^a   Kambayashi, Jun Ichi ^a   Liu, Yongge ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Cilostazol; Heart; Milrinone; OPC 13015; Phosphodiesterase; Platelet; Ventricular myocytes

Indexed keywords

CILOSTAZOL; CYCLIC AMP; DEHYDROCILOSTAZOL; DRUG METABOLITE; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG POTENCY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; ISOLATED HEART; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PLATELETS; COLLAGEN; CORONARY VESSELS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART VENTRICLES; HUMANS; MALE; MILRINONE; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; PERFUSION; PLATELET AGGREGATION INHIBITORS; RABBITS; TETRAZOLES; VASODILATOR AGENTS;

EID: 0032830573     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199910000-00004     Document Type: Article

References (40)

1. Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 1985;35:1198-200.
2. Kamiya T, Sakaguchi S. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung 1985;35:1201-3.
3. Ohashi S, Iwatani M, Hyakuna Y, et al. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung 1985;35: 1203-8.
4. Hiatt WR. Current and future drug therapies for claudication. Vasc Med 1997;2:257-62.
5. Regensteiner J, Stiener J, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104-15.
6. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74.
7. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
8. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18: 1942-7.
9. Food and Drug Administration. FDA approval of cilostazol. Washington, DC: FDA, 1999.
10. Uehara S, Hirayama A. Effects of cilostazol on platelet function. Arzneimittelforschung 1989;39:1531-4.
11. Tani T, Sakurai K, Kimura Y, et al. Pharmacological manipulation of tissue cyclic AMP by inhibitors: effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res 1992;25:215-27.
12. Sheth SB, Colman RW. Regulatory and catalytic domains of platelet cAMP phosphodiesterases: targets for drug design. Semin Hematol 1995;32:110-9.
13. Nagaoka T, Shirakawa T, Kasuya J, et al. Cyclic nucleotide PDE-3: quantitation of PDE-3A and -3B mRNAs in rat tissues by RNase protection assay. Cell Biochem Biophys 1998;29:49-66.
14. Movsesian MA, Komas N, Krall J, et al. Expression and activity of low Km, cGMP-inhibited cAMP phosphodiesterase in cardiac and skeletal muscle. Biochem Biophys Res Commun 1996;225:1058-62.
15. Manganiello VC, Murata T, Taira M, et al. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995;322:1-13.
16. Boger JE, DeLuca SL, Watkins DF, et al. Infusion therapy with milrinone in the home care setting for patients who have advanced heart failure. J Intraven Nurs 1997;20:148-54.
17. Mehra MR, Ventura HO, Kapoor C, et al. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol 1997;80:61-4.
18. Lynch JJJ, Uprichard AC, Frye JW, et al. Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. J Cardiovasc Pharmacol 1989;14:585-97.
19. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
20. Packer M. Treatment of chronic heart failure. Lancet 1992;340: 92-5.
21. Thadani U, Roden DM. FDA panel report: January 1998. Circulation 1998;97:2295-6.
22. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6.
23. Brevetti G, Martone VD, Perna S, et al. Intermittent claudication and risk of cardiovascular events. Angiology 1998;49:843-8.
24. Otsuka America Pharmaceutical, Inc. NDA 20-863: cilostazol. Rockville: Otsuka America Pharmaceutical, 1997.
25. + currents by protein kinase C and adenosine: implications for ischemic preconditioning. Circ Res 1996;78:443-54.
26. Yasunari K, Kohno M, Kano H, et al. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 1997;81:953-62.
27. Garthwaite J, Southam E, Boulton CL, et al. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 1995; 48:184-8.
28. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-74.
29. Laird NM, Lange N, Stram D. Maximum likelihood computations with repeated measures: application of the EM algorithm. J Am Stat Assoc 1987;82:87-105.
30. Darvin H, King T. Lower extremity arterial occlusive disease. Clin Podiatr Med Surg 1992;9:69-77.
31. Manganiello VC, Taira M, Degerman E, et al. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell Signal 1995;7:445-55.
32. Inoue Y, Tochizawa S, Toga K, Tachibana K, Nagamoto M, Sudo T. Effects of OPC-33509 and references on activity of cyclic nucleotide phosphodiesterase type 1, 2, 3A, 3B, 4, 5, and 7 in vitro. Tokushima, Japan: Otsuka Pharmaceutical Co., Ltd. In-House Report 01152, 1997.
33. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9.
34. Lindgren SH, Andersson TL, Vinge E, et al. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol Scand 1990;140:209-19.
35. Pattison A, Astley N, Eason CT, et al. A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood. Thromb Res 1990;57:909-18.
36. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996;36: 403-27.
37. Ikeda U, Ikeda M, Kano S, et al. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol 1996;314:197-202.
38. Tanaka T, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 1988;36:313-20.
39. Komas N, Movsesian M, Kedev S, et al. cGMP-inhibited phosphodiesterase (PDE3). In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase inhibitors. San Diego: Academic Press, 1996:89-102.
40. Lindgren S, Andersson KE. Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat. Acta Physiol Scand 1991;142:77-82.